Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to study results. Image: Adobe Stock ...

KT-621 is an investigational first-in-class once-daily, oral STAT6 degrader with dupilumab-like activity ... the central driver of T helper type 2 (TH2) inflammation in allergic diseases.

The candidate has demonstrated dupilumab-like activity and very good ... KT-621 has the potential to address numerous Th2 diseases, including atopic dermatitis (AD), asthma, chronic obstructive ...